A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients

Yu, JK; Iorio, A; Edginton, AN

Edginton, AN (corresponding author), Univ Waterloo, Sch Pharm, Waterloo, ON, Canada.

THROMBOSIS RESEARCH, 2020; 196 (): 550

Abstract

Introduction: Hemophilia A is a genetic bleeding disorder resulting from a lack of clotting factor VIII. Where extended half-life products are availab......

Full Text Link